Ignite Creation Date:
2025-12-26 @ 4:02 PM
Ignite Modification Date:
2026-04-18 @ 5:25 AM
Study NCT ID:
NCT04218006
Status:
UNKNOWN
Last Update Posted:
2021-04-01
First Post:
2020-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX)
Sponsor:
TRPHARM
Organization:
Study Overview
Official Title:
A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) in Families With Kinship Bonds and at Least One Homozygous Patient
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
F-GENE
Brief Summary:
This is a prospective, non-drug epidemological cohort study aimed to investigate the relatives of these cases with CTX-specific gene mutation and clinical features of CTX disease over CTX index cases diagnosed with CTX disease throughout the clinics in Turkey. Relatives included in the study (relatives of CTX index cases) will be taken into clinical and genetic evaluation. Relatives will not receive any experimental intervention or treatment because of their participation in the study. Therefore, this study does not include a treatment protocol or does not have a predetermined visit flow chart. However, relatives of CTX index cases should give consent to genetic testing.
Detailed Description:
WORK DESIGN STAGES:
1. The CTX index case will be identified and the CTX genetics will be reapproved. The following steps will be provided for all cases.
* Re-validation of CTX genetics: Cases of CTX indexes that are unrelated and clearly identified the CTX homozygous inheritance identified in the CYP27A1 gene by kinship.
* Documenting the nuclear and extended family structure and extracting family trees (interview with index cases and parents of index cases)
* Documentation of all potential symptoms compatible with CTX disease, including data based on the CTX suspicion index (Mignarri Index) in the nuclear and extended family
* Documentation of patients who have died due to unexpected death or unwillingness to participate in the study.
* Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
* Collecting blood samples from index cases and, where possible, all nuclear family members (such as parents and siblings)
2. The target cohort will be defined in each family according to the interview results. If the study physician predicts that there are fewer than 50 patients in a large family for the study and follow-up period, this family will be excluded from the study. The initial objective will be to involve grandparents, all their children, married wives and grandchildren. This choice can be adapted by the physician depending on the special situation in the family according to the results of individuals who have undergone genetic mutation tests in the nuclear family, if any, and the definition of nuclear and extended relatives may change in consanguineous families. All extended family members of each identified CTX case will be invited to perform the following steps:
* Genetic counseling (ideally per family)
* Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara) and no samples will be stored after the analysis and all samples will be destroyed. Documentation of key data for each case
* Confirming that the family tree is correctly identified.
* Documenting patients who have died due to unexpected death or unwillingness to participate in the study.
* Perform limited neurological examination for key signs and symptoms and document it according to the CTX suspicion index (Mignarri Index).
3. Testing all samples by DNA sequencing for the identified mutation analysis. According to the results, large family cohort will be extracted. In some families, this number can reach up to 600-800 cases.
4. Re-inviting all study cases with disease genotypes for extended neurological examination and medical / genetic counseling.
5. To offer genetic counseling to all study patients with carrier genotypes so that they can make informed decisions about marriage and the next generation (the study coordinator will propose the medical follow-up of new cases diagnosed genetically as CTX).
1. The CTX index case will be identified and the CTX genetics will be reapproved. The following steps will be provided for all cases.
* Re-validation of CTX genetics: Cases of CTX indexes that are unrelated and clearly identified the CTX homozygous inheritance identified in the CYP27A1 gene by kinship.
* Documenting the nuclear and extended family structure and extracting family trees (interview with index cases and parents of index cases)
* Documentation of all potential symptoms compatible with CTX disease, including data based on the CTX suspicion index (Mignarri Index) in the nuclear and extended family
* Documentation of patients who have died due to unexpected death or unwillingness to participate in the study.
* Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
* Collecting blood samples from index cases and, where possible, all nuclear family members (such as parents and siblings)
2. The target cohort will be defined in each family according to the interview results. If the study physician predicts that there are fewer than 50 patients in a large family for the study and follow-up period, this family will be excluded from the study. The initial objective will be to involve grandparents, all their children, married wives and grandchildren. This choice can be adapted by the physician depending on the special situation in the family according to the results of individuals who have undergone genetic mutation tests in the nuclear family, if any, and the definition of nuclear and extended relatives may change in consanguineous families. All extended family members of each identified CTX case will be invited to perform the following steps:
* Genetic counseling (ideally per family)
* Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara) and no samples will be stored after the analysis and all samples will be destroyed. Documentation of key data for each case
* Confirming that the family tree is correctly identified.
* Documenting patients who have died due to unexpected death or unwillingness to participate in the study.
* Perform limited neurological examination for key signs and symptoms and document it according to the CTX suspicion index (Mignarri Index).
3. Testing all samples by DNA sequencing for the identified mutation analysis. According to the results, large family cohort will be extracted. In some families, this number can reach up to 600-800 cases.
4. Re-inviting all study cases with disease genotypes for extended neurological examination and medical / genetic counseling.
5. To offer genetic counseling to all study patients with carrier genotypes so that they can make informed decisions about marriage and the next generation (the study coordinator will propose the medical follow-up of new cases diagnosed genetically as CTX).
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: